GH Research Plc GHRS 深 沪
等待开盘 02-06 09:30:00 美东时间
13.66
-1.880
-12.10%
华盛通- 最 高15.24
- 今 开15.24
- 成交量 49.96万股
- 最 低 13.60
- 昨 收 15.54
- 总市值 8.47亿
- 52周最高 19.51
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 7.98
- 委 比 61.34%
- 总股本 6202.94万
- 历史最高 30.43
- 量 比 2.78
- 振 幅 10.55%
- 历史最低 5.05
- 每 手 1
- 风险率 2.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
RBC Capital Maintains Outperform on GH Research, Raises Price Target to $40
RBC Capital analyst Brian Abrahams maintains GH Research (NASDAQ:GHRS) with a Outperform and raises the price target from $33 to $40.
01-23 23:19
美股牛股 | 脑机接口概念持续强势！脑再生科技大涨超60%；Revolution涨超28.6%
脑机接口概念持续强势！脑再生科技大涨超60%，近四日涨幅超150%；“收购传闻”引股价过山车，Revolution隔夜涨超28.6%，盘后跌超6%>>
01-08 15:53
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
GH Research To Provide Update On FDA IND Status And Phase 3 Program For GH001 in Treatment-Resistant Depression On January 5, 2026, At 7:00am EST
GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an
01-03 05:03
GH Research to Announce IND Status for GH001
GH Research PLC, a clinical-stage biopharmaceutical company focused on developing innovative treatments for depression, plans to update stakeholders on January 5, 2026, about the status of its Investigational New Drug (IND) application for GH001 and its global Phase 3 program targeting treatment-resistant depression (TRD). GH001 is a novel mebufotenin therapy administered via a proprietary inhalation method, showing significant results in a Phase...
01-02 21:01
GH Research to Present Promising Results on GH001 at ACNP 2026
GH Research ( ($GHRS) ) has provided an update. GH Research PLC announced its a...
2025-11-24 23:48
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
GH Research Q3 EPS $(0.23) Beats $(0.24) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 2.95 percent. This is unchanged from the same period last year.
2025-11-06 20:19
